HemaCare Corp. reported last week an updated analysis of itsPhase I/II clinical trial of passive hyperimmune therapy (PHT)for treating AIDS.

"The revised data verify the promising nature of thepreliminary data, namely that PHT enhances immunity throughsignificant increases in T4 cell levels and shows a strong trendtoward increasing survival in patients starting treatment withT4 cells between 50-200/cubic millimeter," said Joshua Levy,medical director of the Sherman Oaks, Calif. company(NASDAQ:HEMA).

(c) 1997 American Health Consultants. All rights reserved.

No Comments